ReviewInternational journal of nanomedicine2021
Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment.
Review in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system.Open heart · 2026Article
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.Current pharmaceutical design · 2026Review
- The Pharmacoeconomics and its Evaluation in Enhancing the Indian Healthcare System.Current drug research reviews · 2026Review
- Polymeric Nanocarriers with pH-Dependent Release for Tumor-Specific Delivery.Recent advances in drug delivery and formulation · 2026Review
- Novel Strategies for Precision Diagnosis and Treatment of Prostate Cancer Based on Multifunctional Nanocarrier Systems.International journal of nanomedicine · 2026Review
- A Complete Sojourn of Liposomes in Breast Cancer Therapy: Types, Preparation Techniques, Lipid Selection, and Critical Quality Attributes.Current drug research reviews · 2026Review
- Engineering pH-Responsive Nanocarriers via an Optimized Synthesis of PMOXA-b-PDPA Amphiphilic Diblock Copolymers.Macromolecular rapid communications · 2025Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
- Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin - an approach for enhanced cancer therapy.RSC advances · 2025Article
- Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy.Bioengineering (Basel, Switzerland) · 2025Review
- Combating Antibiotic Resistance: Mechanisms, Multidrug-Resistant Pathogens, and Novel Therapeutic Approaches: An Updated Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2025Review
- Research progress on the induction of immunogenic cell death in tumor immunotherapy using a sonodynamic therapy nanoparticle delivery system.Frontiers in immunology · 2025Review
- The impact of oxidative stress and the NRF2-KEAP1-ARE signaling pathway on anticancer drug resistance.Oncology research · 2025Review
- A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting.Designed monomers and polymers · 2025Review
- Recent Nanosolutions Based on Green Propolis Presenting Useful Medical Applications.Current pharmaceutical biotechnology · 2025Review
- Developing the Strategy to Use Silk Spheres for Efficient, Targeted Delivery of Oligonucleotide Therapeutics to Cancer Cells.International journal of nanomedicine · 2025Article
- The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma.Current cancer drug targets · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotherapy is a part of nanomedicine that involves nanoparticles as carriers to deliver drugs to target locations. This novel targeting approach has been found to resolve various problems, especially those associated with cancer treatment. In nanotherapy, the carrier plays a crucial role in handling many of the existing challenges, including drug protection before early-stage degradations of active substances, allowing them to reach targeted cells and overcome cell resistance mechanisms. The present review comprises the following sections: the first part presents the introduction of pharmacoeconomics as a branch of healthcare economics, the second part covers various beneficial aspects of the use of nanocarriers for in vitro, in vivo, and pre- and clinical studies, as well as discussion on drug resistance problem and present solutions to overcome it. In the third part, progress in drug manufacturing and optimization of the process of nanoparticle synthesis were discussed. Finally, pharmacokinetic and toxicological properties of nanoformulations due to up-to-date studies were summarized. In this review, the most recent developments in the field of nanotechnology's economic impact, particularly beneficial applications in medicine were presented. Primarily focus on cancer treatment, but also discussion on other fields of application, which are strongly associated with cancer epidemiology and treatment, was made. In addition, the current limitations of nanomedicine and its huge potential to improve and develop the health care system were presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.